Journal
NATURE COMMUNICATIONS
Volume 13, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-022-34255-z
Keywords
-
Categories
Funding
- Chinook Therapeutics
- Baltimore Polycystic Kidney Disease Research and Clinical Core Center (NIDDK) [P30DK090868]
- Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowships for Research Abroad
- Osamu Hayaishi Memorial Scholarship for Study Abroad
Ask authors/readers for more resources
This study used single cell multiomic analysis to investigate ADPKD and identified cellular heterogeneity as well as signaling pathways associated with disease progression. Additionally, a novel marker, GPRC5A, was discovered and a regulatory enhancer controlling its expression was validated.
Autosomal dominant polycystic kidney disease (ADPKD) is the leading genetic cause of end stage renal disease characterized by progressive expansion of kidney cysts. To better understand the cell types and states driving ADPKD progression, we analyze eight ADPKD and five healthy human kidney samples, generating single cell multiomic atlas consisting of similar to 100,000 single nucleus transcriptomes and similar to 50,000 single nucleus epigenomes. Activation of proinflammatory, profibrotic signaling pathways are driven by proximal tubular cells with a failed repair transcriptomic signature, proinflammatory fibroblasts and collecting duct cells. We identify GPRC5A as a marker for cyst-lining collecting duct cells that exhibits increased transcription factor binding motif availability for NF-kappa B, TEAD, CREB and retinoic acid receptors. We identify and validate a distal enhancer regulating GPRC5A expression containing these motifs. This single cell multiomic analysis of human ADPKD reveals previously unrecognized cellular heterogeneity and provides a foundation to develop better diagnostic and therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available